Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 24, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), hereby announces the filing by Ramot of a new patent application for a unique Cannabinoids exosome delivery platform - CLX, developed by Ramot and their researchers from Tel Aviv University. InnoCan holds worldwide exclusive option agreement to develop and commercialese the CLX and noticed Ramot on the intention to execute the option into full license agreement. The new patent application covers the ability and applications of a loaded exosome with Cannabinoids, enabling its precise release to target organs. This novel technique may allow better drug efficiently targeting different indications.
Exosomes have emerged as promising nanocarriers for drug delivery and targeted therapy. Exosomes can act as "guided missile" targeting specific damaged organs and have an important role in cell-to-cell communication. Exosomes can be loaded with therapeutic ingredients to enhance their potential.
The CLX (Cannabinoids Loaded Exosome) may hold the potential to provide a highly synergistic effect of tissue such as regeneration and anti-inflammatory properties targeting among other potential indications the recovery of infected lung cells and the Central Nervous System - (CNS) diseases.
Figure #1: Prof. Dani Offen, of TAU, Iris Bincovich InnoCan CEO
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/97538_6dd2926e941c8ba8_002full.jpg.
Prof. Offen of Tel Aviv University stated that, "The ability of loading a Cannabinoid to an exosome is not trivial and presented major challenges, which we have now overcome. The ability of such loading technique may open the door to treat a wide-range of different indications where the exosome and Cannabinoids each have therapeutic potential separately and together given their synergistic effect."
"Innocan Pharma continues to lead the advanced development of delivery platforms that will shape the skyrocketing market of Cannabinoids-integrated Pharma," says CEO Iris Bincovich, "Our exceptional diversified team combined with the unique research capabilities are leading InnoCan to the stage-front of the Cannabinoids-Pharmaceutical industry."
Innocan's relationship with Tel Aviv University
Innocan Pharma Ltd., a wholly owned subsidiary of the Company, notified Ramot at Tel Aviv University, the technology transfer company of Tel Aviv University, of its election to exercise its option to enter into a worldwide exclusive license and research agreement with respect to CBD (or other cannabinoids) loaded exosomes, pursuant to the licensing terms already agreed on and set forth in the option agreement which was signed on April 17th 2020. The research and development initiative is led by Professor Daniel Offen, head of the Neurology Laboratoryat Tel Aviv University in the Department of Human Genetics and Biochemistry. Professor Daniel Offen published over 150 original scientific paperson neurodegenerative diseases and is a co-inventor on over a dozen patents. He is a co-founder of several biotechnology companies developing gene and cell therapies for neurological disorders.
Ramot is excited about the fruitful collaboration with Innocan and believes that the new patents and their tremendous potential will lead to new breakthroughs in the field of drug loading and delivery in therapeutics, said Keren Primor Cohen, Ramot's CEO.
About Innocan
Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.
Innocan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administered by injection. Innocan Israel plans, together with Professor Berenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com
Lytham Partners, LLC
Ben Shamsian CPA | Vice President
Direct: 646-829-9701; Cell: 516-652-9004`Shamsian
shamsian@lythampartners.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97538.
